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P R E V I E WNeural surveillance
of skeletal homeostasis
Endowed with sympathetic and peptidergic nerves, the vertebrate skeleton is under constant surveillance by the nervous
system. In addition to pituitary hormone secretion, centrally regulated sympathetic release, as elegantly demonstrated by
Karsenty and colleagues, integrate to control both components of skeletal remodeling, osteoblastic bone formation, and
osteoclastic bone resorption (Elefteriou et al., 2005).The vertebrate skeleton is richly inner- t
vated with adrenergic and peptidergic C
nerve terminals, and these play impor- i
tant roles in bone remodeling. However,
an integrated view of the neural control o
of bone mass has been lacking. In a re- p
cent study (Elefteriou et al., 2005), Kar- c
senty and colleagues extend their previ- f
ous findings that an intact sympathetic l
nervous system (SNS) is required for the u
action of the hypothalamic leptin recep- d
tor on bone formation to show that the h
SNS also plays a critical role in bone re- b
sorption. c
Elefteriou et al. report that mice defi- T
cient in the β-adrenergic receptor, Adrb2, N
have a high bone mass; this further es- (
tablishes a role for the SNS in skeletal r
regulation. The power of the leptin-SNS- r
bone story arises from the ingenuous use
of pharmacological maneuvers in genet-
ically ablated mice. Intracerebroventricular
injection of leptin thus fails to cause
T
bone loss in mice lacking either Ardb2
Sor the enzyme, dopamine β-hydroxylase
(Dbh; Elefteriou et al., 2005; Takeda et
Hal., 2002). It is evolutionarily significant
Lthough that the regulation of bone mass
by central leptin occurs via mechanisms
Ndistinct from those used for body mass
control. C
The authors attribute this high bone
P
mass phenotype in Ardb2−/− mice not
Tonly to an expected increase in osteo-
Pblastic bone formation but also to a sur-
Sprising decrease in osteoclastic bone re-
sorption. They find that Adrb2 signaling
Nin the osteoblast activates an osteoblast-
C
specific transcription factor, ATF4, which C
then upregulates RANK-L, an osteoclasto- V
Pgenic cytokine. As a negative feedback
Smechanism, this proresorptive action can
G
be inhibited by CART, a leptin-regulated
Ahypothalamic neuropeptide that reduces
L
RANK-L expression through nonadrener- r
gic actions. Cart−/− mice therefore lose A
Pmore bone than do wild-type littermates
1
in response to intracerebroventricular
2
leptin (Elefteriou et al., 2005). However,CELL METABOLISM : APRIL 2005he current search for a receptor for
ART prevents a full understanding of o
ts mechanism of action. r
The leptin-SNS-bone story, while dem- t
nstrating a key role for the SNS, pro- a
els our search for other, yet poorly s
haracterized, neurogenic mechanisms a
or skeletal surveillance (Table 1). Like 1
eptin, hypothalamic NPY2 receptors reg- t
late osteoblastic bone formation (Bal- p
ock et al., 2002). Conditional ablation of i
ypothalamic NPY2 receptors increases l
one mass similarly to leptin- or leptin re- m
eptor-deficient mice (Baldock et al., 2002; s
akeda et al., 2002). On the other hand, e
PY null mice have a normal bone mass t
Elefteriou et al., 2003); these opposing r
esults mandate a closer look at NPY’s 2
ole in bone mass regulation. Another mechanism for hypothalamic
able 1. Established and putative molecules involved in neural surveillance of skeletal homeostasis
tructure/
Transmitter Relay Effector Cells Ablation Phenotype
ypothalamus
eptin SNS OB and OC1 ob/ob HBM
db/db HBM
PY Unknown OB NPY2R−/− HBM
NPY−/− Normal
ART Unknown Unknown cart−/− LBM
ituitary
SH Humoral OB and OC2 TSHR−/− LBM
eripheral
NS Adrenergic OB and OC1 Dbh−/− HBM
Adrb2−/− HBM
PY Nerves OB NPY−/− Normal
GRP Nerves OB and OC2 CGRPα−/− LBM
alcitonin Humoral OC2 Calc−/− HBM
IP Nerves OC2 Unknown
ACAP Nerves OB and OC2 Unknown
ubstance P Nerves OC2 Unknown
lutamate Nerves OB and OC2 Unknown
bbreviations: SNS—sympathetic nervous system; OB—osteoblast; OC—osteoclast; HBM—high bone mass;
BM—low bone mass; NPY—neuropeptide Y; NPY2R—NPY2 receptor; CART—cocaine- and amphetamine-
egulated transcript; TSH—thyroid stimulating hormone; TSHR—TSH receptor; Dbh—dopamine β-hydroxylase;
drb2—β2 adrenergic receptor; CGRP—calcitonin gene-related peptide; VIP—vasoactive intestinal peptide;
ACAP—pituitary adenylate cyclase activating peptide; calc—calcitonin.
Action via the osteoblast.
Direct action on the osteoclast.In contrast to leptin and NPY, ablation
f the vascular neuropeptide, CGRPα,
esults in osteopenia due to reduced os-
eoblastic bone formation (Schinke et
l., 2004). CGRP also inhibits bone re-
orption, but its ablation does not yield
n osteoclastic phenotype (Zaidi et al.,
987; Zaidi et al., 2002). It is also uncer-
ain whether CGRP acts centrally on hy-
othalamic receptors or peripherally on
ts osteoblastic receptor after being re-
eased from Aδ and C-type nerve ter-
inals supplying skeletal vessels (Em-
on and Zaidi, 1989). There is limited
vidence, however, that chemical abla-
ion of peptidergic nerves in rodents dis-
upts skeletal integrity (Offley et al.,
005).219
P R E V I E Wsurveillance of the skeleton is through p
the secretion of pituitary hormones. It e
has recently been shown that thyroid w
stimulating hormone (TSH) inhibits skel- b
etal remodeling directly (Abe et al., t
2003). Both osteoclasts and osteoblasts
possess TSH receptors (TSHRs); their b
ihaploinsufficiency in TSHR+/− mice causes
osteoporosis without affecting thyroid l
function. It is also anticipated that other t
anterior pituitary hormones known to n
function only on target endocrine glands N
have direct skeletal effects. t
Based on these considerations, an in- d
tegrative model for skeletal surveillance s
by the hypothalamus is proposed in Fig- e
ure 1. Its first arm is amplitude modu- s
lated (AM) and regulates bone mass a
through changes in circulating levels of pt
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pFigure 1. Frequency (FM)- and amplitude (AM)-modulated arms for hypothalamic surveillance of skeletal ho-
tmeostasis
iShort circuits refer to nonleptinergic, non-NPYergic release of adrenergic neurotransmitters, as well as epi-
nephrine release from the adrenals. In addition, neuropeptide-containing nerves richly innervate bone tissue
and skeletal blood vessels; however, their physiological significance in skeletal homeostasis is unclear.
Abbreviations: NPY—neuropeptide Y; CGRP—calcitonin gene-related peptide; VIP—vasoactive intestinal A
peptide; Sub P—substance P; Glu—glutamate; TSH—thyroid stimulating hormone; TSHR—TSH receptor;
FSH—follicle stimulating hormone; LH—luteinizing hormone; Adrb2—β2-adrenergic receptor; T3 and T4— M
thyroid hormones; E2—estradiol. t
D
f220ituitary hormones. These hormones M
ither regulate bone cells directly, as D
ith TSH, or stimulate the release of T
one-active master hormones from the M
hyroid, adrenals, and gonads. N
A second neurogenic arm regulates
one mass intermittently through changes
n stimulation frequency (frequency modu- S
ation or FM); this arm functions to override
Ahe effects of the AM arm. Signals origi-
T
ating from hypothalamic leptinergic and H
PYergic neurons are relayed via sympa-
Bhetic and other neurotransmitter pathways
r
irectly to bone cells. From a systems H
tandpoint, the FM arm may modify the
Effects of mechanical stimulation during
M
keletal modeling and remodeling (Lev- B
sseur et al., 2003). For example during 4
2eriods of skeletal modeling, physical ac-ivity may generate SNS sparks at peri-
steal nerve endings to prevent exces-
ive subperiosteal bone apposition. In
ontrast, reduced SNS sparking during
nvolution and disuse might counteract the
rofound reduction in osteoblastic bone
ormation and thus attenuate the other-
ise rapid bone loss. These paradigms
re likely to be tested through biomech-
nical studies in mice lacking specific
NS components such as Dbh and
drb2.
Finally, there is an important therapeu-
ic implication. Hypogonadal osteoporo-
is is caused by long-term changes in
ormones of the AM arm. Karsenty’s work
uggests, however, that genetic ablation
f FM components can overcome this
ong-term AM regulation. Thus, Adr2−/−
ice do not lose bone upon ovariec-
omy (Elefteriou et al., 2005). β blockade
ikewise attenuates agonadal bone loss
n normal mice (Takeda et al., 2002). In
umans, in addition to abrogating bone
oss in reflex sympathetic dystrophy, β
lockers have been recently shown to re-
uce the risk of osteoporotic fracture in
etrospective studies (Schlienger et al.,
004). While large prospective studies
re required before definitive conclusions
an be drawn, a designer β blocker holds
romise for use in an aging population
hat is at high risk for both myocardial
nfarction and osteoporotic fracture.
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